Moderna (MRNA) has risen 22.1% in the year-to-date period against the industry’s 2.7% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the company are currently trading above its 200-day moving average.MRNA Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchDespite registering a significant fall in top-line due to lower COVID-19 vaccine sales, Moderna’s shares continue to soar this year on the back of the strong development ...